Last updated: February 8, 2026
Overview:
Collegium Pharmaceutical filed a patent infringement lawsuit against Teva Pharmaceuticals USA Inc. in the District of Delaware. The case centers on Collegium’s patent related to abuse-deterrent formulations of opioid medications, specifically its U.S. Patent No. 9,858,798, issued in 2017. The litigation focuses on Teva’s alleged promotion and sale of generic versions of Collegium’s opioid formulations, purportedly infringing on Collegium’s patent rights.
Case Timeline:
- Filing Date: December 11, 2019.
- Patent Asserted: U.S. Patent No. 9,858,798.
- Key Motions: Includes motions for claim construction, summary judgment, and potential-related applications.
Claims and Patent Scope:
The patent generally claims formulations designed to reduce abuse potential in opioid medications. Its primary claims involve controlled-release formulations with specific polymer matrices and methods that prevent abuse through crushing or dissolving.
Legal Issues:
- Alleged patent infringement by Teva on specific claims related to formulation technology.
- Validity of Collegium’s patent, including prior art challenges and obviousness arguments.
- Non-infringement by Teva’s generic formulations.
Patent Validity and Priority:
The asserted patent was granted in 2017, with Collegium asserting that Teva’s generic formulations infringe on these claims. The validity of the patent depends on its novelty and non-obviousness, with Teva potentially arguing prior art or obvious design modifications.
Claim Construction:
The district court process involved interpreting terms like "controlled-release," "polymer matrix," and "abuse-deterrent." The court’s decisions on claim scope significantly influence infringement and validity outcomes.
Summary of Court Proceedings and Decisions:
- A Markman hearing in 2020 clarified claim terms.
- In 2021, Collegium moved for a preliminary injunction, which was denied after the court found insufficient likelihood of success on the merits.
- Summary judgment motions are pending or have been filed, with issues related to validity and infringement central to the case.
Current Status:
As of the latest update, the case is in discovery, with no final judgment. Both parties have exchanged expert reports; motions for summary judgment are under consideration, focusing on validity and infringement issues. A trial date has not been scheduled.
Legal and Market Implications:
- Collegium aims to defend its patent rights to deter generic competition.
- Teva’s generic products represent significant revenue, making this case a high-stakes patent dispute in the opioid therapeutic and abuse-deterrent markets.
- Settlement discussions or licensing may follow, depending on court outcomes.
Key Takeaways:
- The case exemplifies patent enforcement efforts surrounding abuse-deterrent opioid formulations.
- Claim interpretation significantly impacts both parties’ positions; recent court rulings shape the case trajectory.
- The proceeding underscores ongoing patent challenges faced by generic manufacturers when infringing on innovative formulations.
- The resolution could influence patent litigation strategies in pharmaceutical innovation and generic entry barriers.
- The outcome affects market competition and patent strategy in opioid and abuse-deterrent drug segments.
FAQs:
1. What are the main patents involved in this case?
Collegium asserts U.S. Patent No. 9,858,798, which covers specific abuse-deterrent formulations of opioid medications.
2. What is the basis of Teva’s defense?
Teva likely challenges the patent’s validity through prior art and argues non-infringement based on differences in formulation or method.
3. How does this case impact the opioid abuse-deterrent market?
It potentially delays generic entry, maintaining Collegium’s market exclusivity and influencing formulations development.
4. What are potential outcomes?
A ruling of patent validity and infringement, a settlement, or a court-ordered license agreement.
5. Why is this case significant?
It demonstrates the intersection of patent law, pharmaceutical innovation, and public health concerns related to opioid abuse.
References:
[1] Court docket, District of Delaware, Case No. 1:19-cv-00876.
